A warning letter has been issued to ExThera Medical Corporation for distributing its product to a hospital for compassionate use (CU) without premarket approval.
In the communication, penned by the US Food and Drug Administration (FDA) on February 6, 2026, the California-based medical device maker was also put on notice
According to
Register for free to keep reading
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day